Effect of β blockers in treatment of chronic obstructive pulmonary disease: A retrospective cohort study

BMJ

Volumn 342, Issue 7806, 2011, Pages

  Short, Philip M ^a   Lipworth, Samuel I W ^b   Elder, Douglas H J ^c   Schembri, Stuart ^d   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF ST ANDREWS   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d PERTH ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FORMOTEROL; IPRATROPIUM BROMIDE; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; SALBUTAMOL; SALMETEROL; TERBUTALINE; TIOTROPIUM BROMIDE; STEROID;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; FEMALE; HAZARD RATIO; HOSPITAL ADMISSION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; EMERGENCY TREATMENT; FORCED EXPIRATORY VOLUME; HEART INFARCTION; HOSPITALIZATION; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; VITAL CAPACITY;

ADRENERGIC BETA-ANTAGONISTS; AGED; EMERGENCY TREATMENT; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MYOCARDIAL INFARCTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; STEROIDS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 79955952987     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d2549     Document Type: Article

References (32)

1. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-9. (Pubitemid 36378490)
2. Olenchock BA, Fonarow GG, Pan W, Hernandez A, Cannon CP. Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. Am J Cardiol 2009;103:295-300.
3. Gauld DR, Pain MC, Rubinfeld AR. B blocking drugs and airways obstruction. Med J Aust 1979;2:88.
4. Raine JM, Palazzo MG, Kerr JH, Sleight P. Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane. BMJ 1981;282:548-9. (Pubitemid 11188775)
5. Williams IP, Millard FJ. Severe asthma after inadvertent ingestion of oxprenolol. Thorax 1980;35:160. (Pubitemid 10175902)
6. Chang CL, Mills GD, McLachlan JD, Karalus NC, Hancox RJ. Cardioselective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. Intern Med J 2010;40:193-200.
7. Van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest 2005;127:818-24. (Pubitemid 40775510)
8. Salpeter SR, Ormiston TM, Salpeter EE, Poole PJ, Cates CJ. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med 2003;97:1094-101. (Pubitemid 37185112)
9. Van Gestel YR, Hoeks SE, Sin DD, Stam H, Mertens FW, Bax JJ, et al. Beta-blockers and health-related quality of life in patients with peripheral arterial disease and COPD. Int J Chron Obstruct Pulmon Dis 2009;4:177-83.
10. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005:4:CD003566.
11. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;11:122.
12. Zvezdin B, Milutinov S, Kojicic M, Hadnadjev M, Hromis S, Markovic M, et al. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest 2009;136:376-80.
13. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-97. (Pubitemid 28384881)
14. Van Gestel YR, Hoeks SE, Sin DD, Welten GM, Schouten O, Witteveen HJ, et al. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med 2008;178:695-700.
15. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010;170:880-7.
16. Wheeldon NM, McDevitt DG, Lipworth BJ. Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects. Br J Clin Pharmacol 1992;34:337-43.
17. Lipworth BJ, Irvine NA, McDevitt DG. A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol. Eur J Clin Pharmacol 1991;40:135-9.
18. Lipworth BJ, Irvine NA, McDevitt DG. The effects of chronic dosing on the beta 1 and beta 2-adrenoceptor antagonism of betaxolol and atenolol. Eur J Clin Pharmacol 1991;40:467-71.
19. Lipworth BJ, Brown RA, McDevitt DG. Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of beta 2-adrenoceptor blockade. Br J Clin Pharmacol 1989;28:95-102. (Pubitemid 19195670)
20. Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641-7.
21. Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest 2009;136:1029-38.
22. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Executive summary. Global Initiative for Chronic Obstructive Lung Disease, 2009.
23. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
24. Shah SM, Carey IM, DeWilde S, Richards N, Cook DG. Trends and inequities in beta-blocker prescribing for heart failure. Br J Gen Pract 2008;58:862-9.
25. The Scottish Government. Scottish index of multiple deprivation. Scottish Government, 2009.
26. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977;1:1645-8. (Pubitemid 8124466)
27. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47:2554-60. (Pubitemid 43866389)
28. Soyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007;29:279-83. (Pubitemid 46237383)
29. Lipworth BJ, Williamson PA. Beta blockers for asthma: a double-edged sword. Lancet 2009;373:104-5.
30. Ind PW, Dixon CM, Fuller RW, Barnes PJ. Anticholinergic blockade of beta-blocker-induced bronchoconstriction. Am Rev Respir Dis 1989;139:1390-4. (Pubitemid 19155495)
31. Schembri S, Anderson W, Morant S, Winter J, Thompson P, Pettitt D, et al. A predictive model of hospitalisation and death from chronic obstructive pulmonary disease. Respir Med 2009;103:1461-7.
32. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81.